Reverse engineering human nature

Dr. Kwon is an accomplished executive with extensive operating experience.

Dr. Kwon held a variety of leadership roles as a senior executive at Momenta Pharmaceuticals. Dr. Kwon was most recently Chief Financial and Business Officer at Momenta, where he had responsibility for business development, strategy, finance, investor relations, and commercial. Dr. Kwon led public equity financings raising nearly $500 million and led the company’s sale to Johnson & Johnson for $6.5 billion. Prior to Momenta, Dr. Kwon was a business development professional at Biogen, driving a variety of transactions. Dr. Kwon previously worked at the venture capital firm Advanced Technology Ventures, investing in early stage biotech and medical device companies.

Dr. Kwon is member of the board of directors of ADMA Biologics (Nasdaq: ADMA), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics. He is also a scientific advisor to Lightstone Ventures, a venture capital firm investing in biotech and medical device companies.

Dr. Kwon received a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University.

Dr. Osbourn is an internationally recognized scientist and researcher. Prior to joining Alchemab, Jane served as Vice President of R&D at MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of antibody phage display technology, authored key publications and patents and contributed to the discovery and development of a number of marketed antibody therapies including Humira and Durvalumab.

Additionally, Jane chairs the Cambridge-based cell therapy company Mogrify, serves as a Director of Babraham Bioscience Technologies, and Cambridge Enterprise, and is a member of the Crick Translational Advisory Group. Previously, she served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel, and from 2015-2019, Jane served as Chair of the Board of Directors of the UK BioIndustry Association.

In 2019 Jane was awarded an Order of the British Empire (OBE) in the Queen’s birthday honors for services to drug discovery, development and biotechnology. Additionally, in 2019, Jane was awarded the 2019 Scrip Lifetime Achievement Award for contribution to the pharma industry.

Jane holds a BA in Natural Sciences (First Class: Biochemistry) from the University of Cambridge and a PhD from the John Innes Centre for Plant Science Research in Norwich.

Dr. Cavlan is a biotech builder and former clinician scientist. She joined Alchemab as founding Head of Business having been an Investment Principal at SV Health Investors. Previously, Olivia was a Partner with McKinsey & Company where she was part of the leadership team in the Healthcare Private Equity and Pharmaceutical practices. While at McKinsey, Olivia co-led the global Real World Evidence practice and QuantumBlack biopharmaceutical offering where she led work on target discovery and clinical development. She has also led several global biopharma R&D transformation efforts and developed clinical and commercial strategies for a number of preclinical assets.

Olivia is a Non-Executive Director for the UK BioIndustry Association and a member of the Investment Committee for Cancer Research UK’s (CRUK) Seed fund. She also co-founded and sits on the Board of Directors of Sevenless Therapeutics, a small molecule pain company.

Olivia holds an MBChB in Medicine and a BSc in Pharmacology from Bristol University where she graduated with the top First Class Honors.

Dr. Varley is an expert in biopharmaceutical development with more than 25+ years experience of developing antibodies, proteins and other macromolecules into drugs from Research into the clinic and through to commercialization.    Previously Paul held a similar roles in Cambridge Antibody Technology, AstraZeneca, MedImmune and most recently Kymab.  Previously Paul had also worked at British Biotech, the UK National Institute of Biological Standards and Control (NIBSC) and the U.S. National Institutes of Health. Dr Varley holds a degree in Biomolecular Sciences (First Class) from Portsmouth Polytechnic and a PhD in Biochemistry from the University of Newcastle upon Tyne.

Paul is a member of the British Pharmacopeia (BP) Commission and Chair of BP Expert Advisory Group on Biological and Biotechnological Products (2013 – 2021).  He also currently chairs a MHRA/BP working party on new standards for Biological Medicines (DPS) and is also a member of the European Pharmacopeia (EP) Expert Committee on Monoclonal Antibodies. Paul is also a member of the UK Vaccine Task Force/BIA Manufacturing Advisory Group.

Paul has been involved with many other activities in the Biopharmaceutical / Bioprocessing space including the European Biotech Enterprises (EBE) Biomanufacturing Committee, Bioprocess UK steering group, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotherapeutics group, and BioProNet.

Paul has contributed to many Advisory Boards and related activities during his career including at University of Cambridge Department of Chemical Engineering and Biotechnology, University College London Biochemical Engineering, the UK National Biologics Manufacturing Centre, and the White Rose Universities DTP in Mechanistic Biology.

Dr. Minter is an expert in antibody discovery with over 20 years’ experience leading discovery teams and developing candidate drugs across multiple disease areas. Previously, he was Senior Director in Antibody Discovery and Protein Engineering at AstraZeneca and prior to that was part of Cambridge Antibody Technology (CAT), which later became MedImmune. In addition to antibody discovery, Ralph is known for pioneering new technology platforms within the biologics field. An example of this is phenotypic, or target-agnostic, antibody screening which Ralph instigated and ran for 15 years at CAT/MedImmune and which has yielded many novel therapeutic targets, some of which are now being tested in clinical trials. Ralph is an author on more than 35 papers, frequent invited speaker at antibody conferences and inventor on several patents. Ralph holds a BSc in Pathology and Microbiology from Bristol University and a PhD in Immunology from Durham University.

Dr. Galson is experienced in the development and application of novel technologies in the biotechnology sector. Previously he was the Bioinformatics lead at Kymab Ltd, where his group developed the IntelliSelect® antibody discovery software platform. Jake is also one of the pioneers of immune receptor repertoire sequencing, serving as a member of the AIRR community, and authoring numerous key publications in the area. He has worked at The Oxford Vaccine Group, GSK Vaccines, and University of Zürich, applying this approach to further understand basic immunology, as well as in support of vaccine development, diagnostics, and antibody drug discovery.

Jake holds a BA in Biological Sciences (First Class) and a PhD in Medical Sciences, both from the University of Oxford.

Dr. Finch is accomplished in antibody drug discovery and development, from Target discovery and validation, in vitro and in vivo models, translational biology and early clinical development. She has over 20 years’ experience leading pharmacology and translational biology teams and developing candidate drugs across multiple disease areas, leading a number of projects from conception through to the clinic. She has been involved in several now marketed antibody drug programmes, and latterly was the Clinical lead for two projects at Clinical Phase 1 and 2. She was also an Industry Lead/Biomarker leader on large multicentre personalised medicine cohorts (COPD-MAP, RA-MAP and NOVELTY), and has a wide and varied academic network across disease areas and specialities.  Donna has authored more than 30 papers and is an inventor on several patents. Donna has worked at Glaxo Group Research, Roche Bioscience, Cambridge Antibody Technology, MedImmune and AstraZeneca.

Donna holds a BSc in Pharmacology from Bristol University and a PhD in Molecular Pharmacology from Leicester University.

Professor Ashrafian is a Managing Partner at SV Health Investors and co-founded Alchemab in 2019. Alongside Alchemab he has founded six other SV companies; Cellinta, Enara Bio, Mestag, Sitryx, TrexBio and Zarodex. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee and as a Director of Karus Therapeutics and Imbria.

Previously, Houman co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. He went on to become Vice President and head of the Clinical Science Group at UCB Pharma.

Outside of SV, following completion of his cardiology training, Houman was appointed as an Honorary Consultant Cardiologist in 2011 at the John Radcliffe Hospital in Oxford. He is Visiting Professor and head of Experimental Therapeutics at the University of Oxford. Additionally, Houman is co-founder and Chairman of Weatherden, a boutique clinical development company.

Dr. Kwon is an accomplished executive with extensive operating experience.

Dr. Kwon held a variety of leadership roles as a senior executive at Momenta Pharmaceuticals. Dr. Kwon was most recently Chief Financial and Business Officer at Momenta, where he had responsibility for business development, strategy, finance, investor relations, and commercial. Dr. Kwon led public equity financings raising nearly $500 million and led the company’s sale to Johnson & Johnson for $6.5 billion. Prior to Momenta, Dr. Kwon was a business development professional at Biogen, driving a variety of transactions. Dr. Kwon previously worked at the venture capital firm Advanced Technology Ventures, investing in early stage biotech and medical device companies.

Dr. Kwon is member of the board of directors of ADMA Biologics (Nasdaq: ADMA), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics. He is also a scientific advisor to Lightstone Ventures, a venture capital firm investing in biotech and medical device companies.

Dr. Kwon received a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University.

Dr. Levin joined RA Capital Management in 2015, is a Managing Director on the Investment Team and spearheads a drug discovery effort that has led to the formation of several new companies. Beginning in 2012, and prior to joining the Investment Manager, he was a Vice President at H.I.G. BioVentures. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. Andrew holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.

Dr. Hamer is a Managing General Partner at DCVC Bio, a San Francisco venture capital fund focused on building the next generation of life science companies. He has held positions as Managing Partner and Founder of Monsanto Growth Ventures and Managing Director and Entrepreneur-in-Residence at Burrill & Co. Prior to venture capital, John held senior management positions at Paradigm Genetics Inc./Icoria (NASDAQ::PDGM), including CSO, CEO and EVP for Business Development. John has a PhD in Microbiology from the University of California, Davis and was Professor of Biological Sciences at Purdue University where he was a Packard Fellow and NSF Presidential Faculty Fellow.

Dr. Lee is Chief Executive Officer of Bicycle Therapeutics and Non-Executive Director of Mestag and NodThera Ltd. Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programs across the full spectrum of research and development, established Pfizer’s rare disease strategy, conceptualized and implemented the company’s gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK). Before joining GSK, he lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions.

Kevin holds a degree in pharmaceutical sciences from Nottingham University, and a PhD in pharmacology from Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, UK. Kevin also holds an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick.